Circulating tumour DNA in B‐cell lymphomas: current state and future prospects

Abstract

Circulating tumour DNA (ctDNA) is a highly versatile analyte and an emerging biomarker for detection of tumour‐specific sequences in lymphoid malignancies. Since ctDNA is derived from tumour cells throughout the body, it overcomes fundamental limitations of tissue biopsies by capturing the complete molecular profile of tumours, including those from inaccessible anatomic locations. Assays for ctDNA are minimally invasive and serial sampling monitors the effectiveness of therapy and identifies minimal residual disease below the detection limit of standard imaging scans. Dynamic changes in ctDNA levels measure real‐time tumour kinetics, and early reductions in ctDNA during treatment correlate with clinical outcomes in multiple B‐cell lymphomas. After therapy, ctDNA can effectively discriminate between patients who achieved a complete molecular remission from those with residual treatment‐resistant disease. Serial monitoring of ctDNA after therapy can detect early molecular relapse and identify drug‐resistant clones that harbour targetable mutations. In order for ctDNA to reach its full potential, the standardization and harmonization of the optimal pre‐analytical and analytical techniques for B‐cell lymphomas is a critically necessary requirement. Prospective validation of ctDNA within clinical studies is also required to determine its clinical utility as an adjunctive decision‐making tool.